(Total Views: 280)
Posted On: 03/12/2018 11:54:02 AM
Post# of 72443
Here's what a deal was worth for a possible schizophrenia drug that has only made it through Phase 1 safety testing:
Pfizer sold it to Biogen. Remember that schizophrenia is extremely hard to treat, most drugs have failed in clinical trials, and this has only made it through the safety trial, not (yet) any efficacy trial.
So, what is the value of a drug that has made it into Phase 2 and shown efficacy? Lots more than this.
I found the royalty percentage being in the teens to be interesting.
Quote:
Biogen will pay a fairly modest $75 million upfront for the therapy, with backloaded biobucks of $515 million coming into play, if all goes well, as well as “tiered royalties in the low to mid-teen percentages.”
https://www.fiercebiotech.com/biotech/biogen-...d=48083647
Pfizer sold it to Biogen. Remember that schizophrenia is extremely hard to treat, most drugs have failed in clinical trials, and this has only made it through the safety trial, not (yet) any efficacy trial.
So, what is the value of a drug that has made it into Phase 2 and shown efficacy? Lots more than this.
I found the royalty percentage being in the teens to be interesting.
(0)
(0)Scroll down for more posts ▼
